PubMed Health⌕ Search

Biomedical subjects

P Orchansky

Publications and source records attributed to P Orchansky.

6 recordsLinked to original sources

Two molecular forms of the human interferon-gamma receptor. Ligand binding, internalization, and down-regulation.

The receptors for human interferon-gamma (IFN-gamma) on peripheral blood monocytes and various cells of nonhematopoietic origin were thoroughly characterized and compared. The receptors of all cell types exhibited a similar affinity for IFN-gamma (Kd approximately 1 x 10(-10) M), and in all cases receptor-mediated endocytosis and ligand degradation were demonstrated. However, the receptors differed in their molecular weights (95,000 in HeLa cells and 140,000 in monocytes, assuming a 1:1 ligand to receptor ratio) as concluded from experiments of cross-linking to 125I-IFN-gamma. Lower molecular weight species were obtained as well, particularly in monocytes. Such species could represent either degradation products or subunit structures. The monocyte and HeLa receptor responded differently to an excess of ligand. A significant receptor down-regulation was observed when monocytes were incubated with an excess of 125I-IFN-gamma, whereas no such down-regulation was observed in HeLa cells or in normal fibroblasts. This differential response was observed both in the presence or in the absence of a protein synthesis inhibitor. The receptor on monocytes was found to be acid-labile whereas that on HeLa cells was resistant to acid treatment. These and additional experiments indicate that the monocyte receptor is inactivated following internalization, whereas the HeLa receptor retains its structure and recycles back to the cell surface. The difference in the properties and fate of these two receptor subtypes is probably related to the differential functions of IFN-gamma in various cell types.

Binding Sites↗

The human interferon-gamma receptor. Purification, characterization, and preparation of antibodies.

The receptor for human interferon-gamma (IFN-gamma) was purified from foreskin fibroblasts. Triton X-100 extracts obtained from either intact cells or membrane preparations were passed through an immobilized interferon-gamma column. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of eluted fractions revealed a major band of Mr = 95,000 and minor bands of Mr = 80,000 and 60,000. Further purification was obtained by steric exclusion and by lectin chromatography. The purified receptor retained the ability to bind 125I-IFN-gamma with a Kd of 2.2 X 10(-10) M, a value close to that obtained with intact fibroblasts (5 X 10(-10) M). A complex of Mr = 105,000-125,000 was visualized by immunoprecipitation of 125I-IFN-gamma cross-linked to the purified receptor followed by SDS-PAGE and autoradiography. A similar complex was obtained when 125I-IFN-gamma was cross-linked to intact cells. Immunization of mice with the excised SDS-PAGE band of Mr = 95,000 elicited antibodies that blocked the antiviral activity of IFN-gamma and immunoprecipitated the cross-linked complex of 125I-IFN-gamma and its receptor.

Antibodies↗

The interferon receptors.

Early studies on the mode of action of interferons have indicated that a receptor system on the cell surface is involved in its action. The first direct evidence to a high-affinity binding site was found only after pure interferon was available. Two different receptors, one specific for interferons-alpha and beta, and the other for interferon-gamma were recognized. A correlation between affinity to the receptor and specific activity was established. Cross-linked complexes of labeled interferons with their receptors were visualized on gel electrophoresis and even partially purified. Internalization of interferons after binding to the receptor was reported. The role of gangliosides as helpers of interferon binding was recently investigated. Fragments of interferons which still retained binding capacity were described and helped in elucidating the binding site on the interferon molecule.

Animals↗

The interferon-gamma receptor in human monocytes is different from the one in nonhematopoietic cells.

The receptor for interferon-gamma (IFN-gamma) on peripheral blood monocytes was characterized and was compared with that of human WISH cells. 125I-IFN-gamma was specifically bound to both cells; however, different binding characteristics were obtained. In the case of monocytes, Scatchard analysis gave an upward concave dependency curve, indicating either multiple binding sites or a negative cooperativity among the binding sites. In contrast, a linear Scatchard plot was obtained for the binding in WISH cells. Competition studies gave even more striking differences. Acid-treated IFN-gamma (95% inactivated) effectively competed with 125I-IFN-gamma for binding to the receptor on WISH cells, but not on monocytes. The significance of these differences was evaluated by analyzing the various biological activities of IFN-gamma in these two cell types. IFN-gamma was found to induce an antiviral state in WISH cells, but not in monocytes. Acid-treated IFN-gamma was found to be almost as active as IFN-gamma itself in inducing HLA-DR in WISH cells, but was almost completely inactive as an HLA-DR inducer in monocytes. It is proposed that these variations in biological activity stem from the presence of different receptors for IFN-gamma in monocytes and in WISH cells. Moreover it is suggested that the immunoregulatory functions of IFN-gamma in monocytes are related to the presence of a distinct IFN-gamma receptor in these cells.

Amnion↗

Type I and Type II interferon receptors.

Binding site competition studies of 125I-interferon (IFN)-gamma were performed with homogeneous preparations of IFNs alpha 2, beta, and gamma. It was found that only IFN-gamma could compete for the specific binding site of 125I-IFN-gamma in both WISH and FS11 cells. Thus, a clear distinction between the receptor of IFN- alpha and beta on one hand, and the receptor of IFN-gamma on the other hand, was obtained. This result is unambiguous because all IFN preparations which were used were purified to homogeneity by specific monoclonal antibody immunoaffinity chromatography. We propose to assign the names "Type I" for the receptor of IFN-alpha and IFN-beta, and "Type II" for the specific receptor of IFN-gamma.

Binding, Competitive↗

Human interferons protect plants from virus infection.

Unfractionated human leukocyte interferon, as well as highly purified subspecies of this interferon, and a purified recombinant of human leukocyte interferon produced in bacteria are active in suppressing multiplicability of tobacco mosaic virus in tobacco leaf discs. Human fibroblast interferon exhibits diverse levels of antiviral activity against tobacco mosaic virus but becomes as active as human leukocyte interferon upon incubation with glycosidases. The effect of interferon is reversible; normal multiplication of tobacco mosaic virus resumes upon removal of interferon.

Enzyme-Linked Immunosorbent Assay↗